Status:

RECRUITING

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

Lead Sponsor:

The Netherlands Cancer Institute

Collaborating Sponsors:

Dutch Cancer Society

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Brief Summary

This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The st...

Eligibility Criteria

Inclusion

  • Patients aged 18 years or older
  • Histologically confirmed adenocarcinoma of the breast
  • Assumed clinical or pathological stage III (TNM) breast cancer
  • Breast tumor must be:
  • HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH)
  • Hormone receptor negative i.e. an estrogen receptor (ER) of \<10% and progesterone receptor (PR) of \<10%.; or in case of a histological grade III tumor an ER of \<50% and a PR of \<50%.
  • Patients are planned to receive the complete standard of care in the Netherlands; neo-adjuvant chemotherapy according to local practise
  • Participating patients have to be able to use a mobile phone, tablet, laptop and/or computer and understand the Dutch language

Exclusion

  • Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines.
  • Patients who are only treated systemically in the adjuvant setting
  • Participation in another clinical study with an treatment intervention during the course of this study.

Key Trial Info

Start Date :

November 6 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2030

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06931769

Start Date

November 6 2025

End Date

July 1 2030

Last Update

November 26 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Medical spectrum Twente

Enschede, Overijssel, Netherlands, 7500 KA

2

Amsterdam University Medical Center

Amsterdam, Netherlands

3

The Netherlands Cancer Institute

Amsterdam, Netherlands

4

UMCG

Groningen, Netherlands, 9713 GZ